In T2DM, β-Cell Mass in Islets is Significantly Reduced

Slides:



Advertisements
Similar presentations
Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Advertisements

Susan Alexander, DNP, CNS, CRNP, BC- ADM College of Nursing University of Alabama in Huntsville Clinical Affiliation: Outpatient Diabetes Self-Management.
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
LONG TERM BENEFITS OF ORAL AGENTS
Therapy of Type 2 Diabetes Mellitus: UPDATE
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 1.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes Mellitus 101 for Medical Professionals
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
A Diabetes Outcome Progression Trial
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Beta Cell Mass in Type 2 DM Gepts et al McClean et al Westermark et al Saito et al Stefan et al Ann Roy Sci Med Nat 10:1, 1957 Reduced Diabetes 4:367,
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Lifestyle Modifications
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Type I Diabetes Juvenile diabetes – develops early in life Beta cells in pancreas do not produce insulin Genetic predisposition – virus may trigger an.
Current Classification of DM Update on Diabetes Classification Celeste C. Thomas, MD, MSa,*, Louis H. Philipson, MD, PhD,Med Clin N Am 99 (2015) 1–16.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
A Process Of Precision Medicine- Matching Right Drug to Right Patient.
Utilizing Anti-diabetic Agents to Manage Cardiovascular Disease in T2DM Patients James LaSalle, D.O., FAAFP.
Diabetes in the Pediatric Population
CV Risk of SU and Insulin
Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises.
The β-Cell Centric Classification of DM
A Process Of Precision Medicine- Matching Right Drug to Right Patient
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
Visfatin in Type 2 Diabetes Mellitus
WHAT ABOUT COMPLICATIONS OF DIABETES?
Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.
Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits.
Initiation of Basal Insulin- not bolus
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Targets for Therapies/ New Guidelines
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Pushback What about ‘pure’ Insulin Resistance Syndromes?
Therapy of Type 2 Diabetes Mellitus: UPDATE
CV Risk of SU and Insulin
Macrovascular Complications Microvascular Complications
The Next Generation of Basal Insulins
Value of construct 1. Fits with Harry Keen’s construct
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
Figure 4 Effect of dapagliflozin on HbA1c and body weight
↑- likely due to hypoglycemia and weight gain
Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!
WHAT ABOUT COMPLICATIONS OF DIABETES?
Insulin Secretagogues: Sulfonylureas and “Glinides”
Diabetes Journal Club March 17, 2011
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Diabetes mellitus II - III First and second type of diabetes mellitus
Not just cost of a dose, but cost benefit of CV/Complication reduction
Presentation transcript:

In T2DM, β-Cell Mass in Islets is Significantly Reduced Control T2DM 35% -cells 65% β-cells 52% -cells 48% β-cells P <0.01 Adapted from Deng S, et al. Diabetes. 2004;53:624-632.

So ‘maybe’ Insulin need in T2DM overstated  Phenotypic Presentation is defined by: Slope = ‘Natural History’ over time,i.e.,RATE OF β-cell LOSS. Slope is not linear in either T1DM or T2DM, and may be intermittently relapsing, remitting, stabilized, and improved. Complete loss of β-cell mass may never be reached, especially if newer agents better preserve β-cells. 100% − 0% − Severity = β-cell loss of mass Beta cell mass is a function of relative rates of apoptosis, replication and neogenesis Pre-Diabetes = FBS ≥100, PPG ≥140 All DM = FBS ≥126, PPG ≥200 Critical β−Cell Mass % β−Cell Mass Disease Modification I I I I I/ ≈ / I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Increasing Age Age at presentation = tipping point when the combined gene effect / environmental trigger is exposed as phenotypic hyperglycemia

DURABILITY OF GLYCEMIC CONTROL WITH SULFONYLUREAS 1 Glyburide Glyburide Glimepiride SU Glyburide GLY Alvarsson (n=39) SU Alvarsson (n=48) Gliclazide RECORD (n=272) Change in HbA1c (%) Glyburide Hanefeld (n=250) Charbonnel (n=313) -1 Gliclazide UKPDS (n=1,573) Chicago (n=230) ADOPT (n=1,441) PERISCOPE (n=181) Tan (n=297) -2 1 2 3 4 5 6 10 TIME (years) 3

a Myth Natural History- Usual ‘Story’- Progressive Loss of Mass Requiring Insulin Therapy in Many/Most- a Myth 1. Progressive Decline in Function – multiple causes of b-cell damage- decreased function>mass- worse with with SU/ Insulin TX BUT 2. Med School- need to do 80% pancreatectomy to become diabetic 3. “..no more than 20-25% of pancreas needed to stay normal after distal pancreatectomy (King-from ref. below ) 4. After Bariatric surgery- even 20 years DM, 15 on insulin- 3 days later no need for insulin, Or , often, on no anti-dm medicine at all So.. Have more b-cells after years than most believe So.. No Sulfonylurea- destroys b-cells; Delay Insulin- avoid effects of hyperinsulinism- hypo- wt.gain Use agents that preserve B-cell function (DeFronzo’s Triple Therapy) -and may decrease CV outcomes So.. No need for early insulin If need insulin- one can avoid bolus in most !! . J Gastrointest Surg (2008) 12:1548–1553,Distal Pancreatectomy: Incidence of Postoperative Diabetes Jonathan King & Kevork Kazanjian & J. Matsumoto & Howard A. Reber & Michael W. Yeh & O. Joe Hines & Guido Eibl

Exquisitely controlled levels of insulin released into the portal vein NOTE: There is NO perfect Exogenous Insulin: All result in HyperInsulinemia and Potential Hypoglycemia Exquisitely controlled levels of insulin released into the portal vein Fine-tuned, physiologically appropriate insulinemia Endogenous Insulin ‘Obligatory’ excess peripheral insulin to get modicum of reduced hepatic glucose production Exogenous Insulin Insulin Resistance β-cell Dysfunction ------- Potential β-cell Exhaustion Hypoglycemia Obesity Hyperinsulin-emia Atherosclerosis All because all insulin results in hyperinsulinemia with risk of negative consequences Weight gain Hypertension Dyslipidemia Cancer Chronic Inflammation Type II Diabetes

Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises Undue Basal Or bolus Insulin =Overinsulinized Patient eats too much Or simple sugars Hypoglycemia Symptomatic or not! INCREASED APPETITE

ORIGIN TRIAL With Early Insulin Therapy No Benefit in reducing Adverse CV Outcomes and increased hypoglycemia and wt. gain

Increased Mortality, MACE, Cancer 1-year After Starting insulin- 2014 Diabetes Obes Metab. 2014 Nov 14. doi: 10.1111/dom.12412. [Epub ahead of print] Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association  with all-causemortality, cardiovascular events and cancer. Holden SE1, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ.

Value to Early Insulin Therapy- Outweighed By Hypoglycemia Weight Gain ….